04Jun
Cannabis-Derived Ingredients in FDA-Regulated Products: More Questions than Answers at FDA’s May 2019 Public Hearing
As most folks with any interest in the burgeoning cannabidiol (CBD) industry likely know, on May 31, 2019, the Food and Drug Administration held a public hearing “to obtain scientific data and information about the safety, manufacturing, product...
By:
Mintz - Consumer Product Safety Viewpoints
Related
The Delaware Court of Chancery’s 2016 decision in In re Trulia Stockholder Litigation sought to add...
Read More >
2019 has brought a flurry of new leave and accommodation laws. In fact, in the first 8 months of 20...
Read More >
Today, the National Labor Relations Board (“NLRB”) publicized its restructuring of some union elec...
Read More >
This Article discusses the effect of COVID-19 and the various ensuing government shutdowns and restr...
Read More >
In today’s competitive and fast-paced life sciences dealmaking environment, buyers and investors ar...
Read More >
On September 14, 2020, Division One of the Washington Court of Appeals provided clarification in the...
Read More >